Navigation Links
Smith & Nephew CEO Interviewed on Q2 2011 Results
Date:8/5/2011

LONDON, August 5, 2011 /PRNewswire/ --

 

Medical devices group Smith & Nephew reports sales growth of 12% and underlying sales growth of 5%.

In an interview with financial broadcaster http://www.cantos.com, new CEO Olivier Bohuon talks Q2 results and introduces his plans for a new Strategic Framework that details efficiency plans and announces a new focus on emerging markets. 

Bohuon also announced plans to inject an additional $300m into R&D over the next five years, and to focus the business on performance, innovation and a more global presence.

The interview and transcript are available now on http://www.cantos.com/company/Smith%20and%20Nephew

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@cantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE Smith & Nephew plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. Canadas Michael Smith Genome Sciences Center Validates NEBNextâ„¢ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
6. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
7. SpineSmith to Present at the 5th Annual Stem Cell Summit
8. SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement
9. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
10. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
11. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
(Date:1/23/2017)... ... January 23, 2017 , ... Calvert Labs, Inc. announced ... and Senior Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and Ph.D. ... career as an academic and industry preclinical drug developer spans more than three ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec 15, 2016 ... Research and Markets has announced the ... their offering. The report forecasts the global military biometrics ... The report has been prepared based on an in-depth ... landscape and its growth prospects over the coming years. The report also ...
(Date:12/15/2016)... LONDON , Dec. 14, 2016 "Increase ... mobile biometrics market" The mobile biometrics market is expected ... USD 49.33 billion by 2022, at a CAGR of ... by factors such as the growing demand for smart ... mobile transactions. "Software component is expected to ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
Breaking Biology News(10 mins):